| Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I–III triple-negative breast cancer (NeoSTOP) P Sharma, BF Kimler, A O'Dea, L Nye, YY Wang, R Yoder, JM Staley, ... Clinical Cancer Research 27 (4), 975-982, 2021 | 69 | 2021 |
| Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC)(NeoPACT). P Sharma, SR Stecklein, R Yoder, JM Staley, K Schwensen, A O'Dea, ... Journal of Clinical Oncology 40 (16_suppl), 513-513, 2022 | 48 | 2022 |
| Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer R Yoder, BF Kimler, JM Staley, K Schwensen, YY Wang, K Finke, A O’Dea, ... npj Breast Cancer 8 (1), 1-7, 2022 | 26 | 2022 |
| Making Sense of Pharmacovigilance and Drug Adverse Event Reporting: Comparative Similarity Association Analysis Using AI Machine Learning Algorithms in Dogs and Cats X Xu, R Mazloom, A Goligerdian, J Staley, M Amini, G Wyckoff, J Riviere, ... Topics in Companion Animal Medicine, 100366, 2019 | 22 | 2019 |
| ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease SR Stecklein, BF Kimler, R Yoder, K Schwensen, JM Staley, QJ Khan, ... NPJ Breast Cancer 9 (1), 10, 2023 | 17 | 2023 |
| Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial P Sharma, SR Stecklein, R Yoder, JM Staley, K Schwensen, A O’Dea, ... JAMA oncology 10 (2), 227-235, 2024 | 14 | 2024 |
| Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC). P Sharma, VG Abramson, A O'Dea, LE Nye, IA Mayer, GJ Crane, M Elia, ... Journal of Clinical Oncology 39 (15_suppl), 1076-1076, 2021 | 10 | 2021 |
| Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis … SR Stecklein, R Yoder, JM Staley, Z Schmitt, A O'Dea, LE Nye, M Elia, ... Journal of Clinical Oncology 41 (16_suppl), 507-507, 2023 | 5 | 2023 |
| Novel Data Sharing Agreement to Accelerate Big Data Translational Research Projects in the One Health Sphere J Staley, R Mazloom, P Lowe, CT Newsum, M Jaberi-Douraki, J Riviere, ... Topics in Companion Animal Medicine 37 (December 2019), 100367, 2019 | 5 | 2019 |
| Abstract P2-01-05: Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease P Sharma, SR Stecklein, BF Kimler, R Yoder, K Schwensen, JM Staley, ... Cancer Research 82 (4_Supplement), P2-01-05-P2-01-05, 2022 | 3 | 2022 |
| Extinction of chromosomes due to specialization is a universal occurrence J Wilson, JM Staley, GJ Wyckoff Scientific Reports 10 (1), 2170, 2020 | 3 | 2020 |
| Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy M Martín, R Yoder, R Salgado, M del Monte-Millán, EL Álvarez, ... Clinical Cancer Research 30 (10), 2160-2169, 2024 | 2 | 2024 |
| Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD). SR Stecklein, D Koestler, NK Yellapu, R Yoder, BF Kimler, JM Staley, ... Journal of Clinical Oncology 41 (16_suppl), 578-578, 2023 | 2 | 2023 |
| Abstract PD11-07: PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a … P Sharma, SR Stecklein, R Yoder, JM Staley, R Salgado, L Paré, B Conte, ... Cancer Research 83 (5_Supplement), PD11-07-PD11-07, 2023 | 2 | 2023 |
| Abstract PD1-06: Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from … SR Stecklein, R Yoder, R Salgado, JM Staley, A O’Dea, L Nye, M Elia, ... Cancer Research 83 (5_Supplement), PD1-06-PD1-06, 2023 | 1 | 2023 |
| Abstract PS6-04: Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2 negative breast cancer R Yoder, BF Kimler, JM Staley, K Schwensen, YY Wang, K Finke, A O'Dea, ... Cancer Research 81 (4_Supplement), PS6-04-PS6-04, 2021 | 1 | 2021 |
| NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte-and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC). SR Stecklein, A Aripoli, R Salgado, A O'Dea, LE Nye, KE Larson, D Satelli, ... Journal of Clinical Oncology 42 (16_suppl), TPS629-TPS629, 2024 | | 2024 |
| Abstract PS16-09: Analysis of the Radiosensitivity Index/Genomic-Adjusted Radiation Dose (RSI-GARD) in Paired Pre-and Post-Treatment TNBC Samples: Implications for Biomarker … S Stecklein, J White, R Yoder, J Staley, Z Schmitt, A O'Dea, L Nye, ... Cancer Research 84 (9_Supplement), PS16-09-PS16-09, 2024 | | 2024 |
| Abstract PS16-07: Tumor infiltrating lymphocyte stratification refines AJCC TNM staging based outcomes of early-stage triple negative breast cancer treated with neoadjuvant … M Martín, R Yoder, R Salgado, M Monte-Millán, E Álvarez, I Echavarria, ... Cancer Research 84 (9_Supplement), PS16-07-PS16-07, 2024 | | 2024 |
| Abstract PO2-13-07: SMARCA2 compensation of SMARCA4 loss mediates adaptive resistance to neoadjuvant systemic therapy in triple-negative breast cancer: paired transcriptomic … S Stecklein, R Yoder, J Staley, Z Schmitt, A O'Dea, L Nye, D Satelli, ... Cancer Research 84 (9_Supplement), PO2-13-07-PO2-13-07, 2024 | | 2024 |
Andrew K. Godwin, PhDProfessor and Division Director, University of Kansas Medical Center在 kumc.edu 的电子邮件经过验证
